A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Overview

About this study

The purpose of this study is to assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Key Inclusion Criteria:

  • Males or non-pregnant females aged between 18 and 75 years (inclusive) at time of signing the informed consent form (ICF).
  • At least 1 metabolic risk factor.
  • Biopsy-confirmed fibrosis stage F4 MASH (per non-alcoholic steatohepatitis [NASH] Clinical Research Network (CRN) system) with compensated cirrhosis.
  • Body mass index (BMI) at screening ≥25.0 (≥23.0 for Asian participants) and <50.0 kilograms (kg)/meters squared (m^2).

Key Exclusion Criteria:

  • Liver disorder other than MASH.
  • History or evidence of hepatic decompensation.
  • History or evidence of hepatocellular carcinoma.
  • Have type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus.
  • ALT or aspartate aminotransferase (AST) ≥250 units per liter (U/L).
  • Participants taking vitamin E (>400 international units [IU]/day) must be on stable dose for at least 6 months prior to screening.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/17/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Manal Abdelmalek, M.D.

Contact us for the latest status

Contact information:

Carlos Sanchez Gonzalez

(507) 266-0976

SanchezGonzalez.Carlos@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Maria Yataco, M.D.

Contact us for the latest status

Contact information:

Frank LoCascio

(507) 738-6155

LoCascio.Frank@mayo.edu

More information

Publications

Publications are currently not available